COVID 19 Supplemental work: HIGH THROUGHPUT BIOMARKER-BASED BIODOSIMETRY

COVID 19 补充工作：基于高通量生物标志物的生物剂量测定

• 批准号: 10260009
• 负责人: GEORGE SIGAL
• 金额: $ 149.97万
• 依托单位: MESO SCALE DIAGNOSTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-03-15 至 2021-05-10
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10260009
• 关键词: 2019-nCoV; Address; Antibodies; Biological Assay; Biological Markers; COVID-19; Collaborations; Diagnosis; Epidemiology; Immunity; Measurement; Reagent; Saliva; Serologic tests; Vaccines; Work; base; biodosimetry; experience; reagent testing; vaccine trial

The company is working to develop serology assays for CoV-2 vaccine studies. The project leverages experience in developing and manufacturing high-throughput serology assays, and addresses the need for high quality CoV-2 reagents and tests that can be reproducibly manufactured at large scale. They also propose a study – in collaboration with Kaiser Permanente - to evaluate measurement of antibodies in saliva to assess immunity to SARS-CoV-2.

该公司正在努力开发用于CoV-2疫苗研究的血清学检测方法。 该项目利用了开发和制造高通量血清学检测的经验，并解决了对高质量CoV-2试剂和检测的需求，这些试剂和检测可以大规模重复生产。 他们还提议与Kaiser Permanente合作进行一项研究，评估唾液中抗体的测量，以评估对SARS-CoV-2的免疫力。